Lexicon Pharmaceuticals 将来の成長

Future 基準チェック /16

Lexicon Pharmaceuticals利益と収益がそれぞれ年間15.4%と14.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-33.9% 21.4%なると予測されています。

主要情報

15.4%

収益成長率

21.42%

EPS成長率

Pharmaceuticals 収益成長	12.8%
収益成長率	14.5%
将来の株主資本利益率	-33.94%
アナリストカバレッジ	Low
最終更新日	10 Dec 2025

今後の成長に関する最新情報

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

May 17

Recent updates

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Dec 18

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

Dec 03

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

Oct 02

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump

Jul 28

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%

Jun 13

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts

May 19

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

May 17

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Apr 01 Advancing novel medicines like pilavapadin and LX9851 could significantly impact revenue growth and open high-demand markets.

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Mar 28

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Mar 26

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Oct 16

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

業績と収益の成長予測

NasdaqCM:LXRX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	61	-74	N/A	N/A	3
12/31/2027	18	-107	N/A	N/A	4
12/31/2026	15	-107	N/A	N/A	5
12/31/2025	47	-63	N/A	N/A	5
9/30/2025	71	-69	-73	-72	N/A
6/30/2025	58	-121	-103	-102	N/A
3/31/2025	31	-177	-168	-167	N/A
12/31/2024	31	-200	-180	-179	N/A
9/30/2024	5	-216	-208	-208	N/A
6/30/2024	4	-202	-196	-196	N/A
3/31/2024	2	-194	-186	-185	N/A
12/31/2023	1	-177	-162	-162	N/A
9/30/2023	1	-158	-135	-133	N/A
6/30/2023	0	-131	-112	-111	N/A
3/31/2023	0	-110	-99	-97	N/A
12/31/2022	0	-102	-90	-89	N/A
9/30/2022	0	-97	-90	-90	N/A
6/30/2022	0	-97	-88	-88	N/A
3/31/2022	0	-90	-87	-85	N/A
12/31/2021	0	-88	-88	-87	N/A
9/30/2021	0	-68	-100	-98	N/A
6/30/2021	7	38	38	-122	N/A
3/31/2021	16	-13	14	-146	N/A
12/31/2020	24	-59	17	-143	N/A
9/30/2020	33	-104	27	-133	N/A
6/30/2020	320	39	98	98	N/A
3/31/2020	321	85	117	117	N/A
12/31/2019	322	130	114	114	N/A
9/30/2019	330	164	111	111	N/A
6/30/2019	43	-89	N/A	-102	N/A
3/31/2019	47	-101	N/A	-127	N/A
12/31/2018	63	-121	N/A	-149	N/A
9/30/2018	81	-126	N/A	-155	N/A
6/30/2018	101	-129	N/A	-167	N/A
3/31/2018	99	-130	N/A	-147	N/A
12/31/2017	92	-123	N/A	-185	N/A
9/30/2017	80	-133	N/A	-200	N/A
6/30/2017	81	-138	N/A	-202	N/A
3/31/2017	89	-141	N/A	-217	N/A
12/31/2016	79	-131	N/A	-176	N/A
9/30/2016	188	-22	N/A	139	N/A
6/30/2016	160	-22	N/A	149	N/A
3/31/2016	141	-11	N/A	165	N/A
12/31/2015	130	-5	N/A	185	N/A
9/30/2015	24	-94	N/A	-86	N/A
6/30/2015	24	-100	N/A	-81	N/A
3/31/2015	24	-98	N/A	-69	N/A

アナリストによる今後の成長予測

収入対貯蓄率: LXRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: LXRX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: LXRX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: LXRXの収益 ( 14.5% ) US市場 ( 10.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: LXRXの収益 ( 14.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: LXRX 3 年以内に赤字になると予測されています。

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/06 13:25
終値	2026/01/05 00:00
収益	2025/09/30
年間収益	2024/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Lexicon Pharmaceuticals, Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。12

アナリスト	機関
Yigal Nochomovitz	Citigroup Inc
Joseph Pantginis	H.C. Wainwright & Co.
Andrew Tsai	Jefferies LLC

Lexicon Pharmaceuticals 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Price target increased by 17% to US$3.05

Consensus revenue estimates increase by 48%

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

Price target decreased by 13% to US$4.68

Consensus revenue estimates decrease by 24%

Price target increased by 16% to US$6.25

Recent updates

New major risk - Revenue and earnings growth

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals, Inc. Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Ayl-Coa Synthetase 5 (Acsl5) Reinforcing the Scientific Rationale for Lx9851

Lexicon Pharmaceuticals, Inc. Announces Clinical Data on Adipose Distribution in Non-Diabetic Patients to Be Presented At the 2025 Cardio Vascular Clinical Trialists Forum

Lexicon Pharmaceuticals Has Multiple Paths To Upside, But Formidable Hurdles As Well

New major risk - Revenue and earnings growth

Lexicon Pharmaceuticals, Inc. Announces Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure Without Diabetes Presented At American Heart Association Annual Scientific Sessions 2025

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Lexicon Pharmaceuticals, Inc. Announces Data from Three Studies of Sotagliflozin to Be Presented At the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Lexicon Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025

Lexicon Pharmaceuticals, Inc. Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 28%

Lexicon Pharmaceuticals, Inc. Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista®? in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. Announces the Presentation of Clinical Data from the Company's Phase 2B Progress Study for Its Investigational, AAK1-Inhibitor, Pilavapadin, for the Treatment of Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista®? in Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. Presents Post-Hoc Analysis of Sotagliflozin Among Older Adults

Second quarter 2025 earnings released

Price target increased by 17% to US$3.05

There's Reason For Concern Over Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Massive 34% Price Jump

Lexicon Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 06, 2025

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Clinical Study Data Showing A Reduction in Hypoglycemia Events When Added to Optimized Insulin

Revenues Not Telling The Story For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) After Shares Rise 31%

Consensus revenue estimates increase by 48%

Lexicon Pharmaceuticals, Inc. Announces Details of Its "Sotagliflozin" in Patients with Symptomatic Obstructive and Non-Obstructive Hypertrophic Cardiomyopathy (Hcm) Study

Analysts Just Made A Noticeable Upgrade To Their Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Forecasts

Earnings Update: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Just Reported And Analysts Are Boosting Their Estimates

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 13, 2025

Pilavapadin Trials And LX9851 Development Will Expand Treatment Options

Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade)

Investors Don't See Light At End Of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Tunnel And Push Stock Down 50%

Lexicon Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q4, 2024 Results on Mar 06, 2025

Lexicon Pharmaceuticals, Inc. Publishes Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events

New major risk - Shareholder dilution

Lexicon Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Lexicon Pharmaceuticals, Inc. Announces CFO Changes

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Price target decreased by 13% to US$4.68

Lexicon Pharmaceuticals, Inc. Announces Board Changes

Consensus revenue estimates decrease by 24%

New major risk - Financial position

Price target increased by 16% to US$6.25

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 16% to US$5.40

Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Consensus revenue estimates increase by 33%

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces Management Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much